Patricia M LoRusso
Yale University Cancer Center LAO · Karmanos Cancer Institute Hudson-Webber Cancer Research Center · Barbara Ann Karmanos Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patricia M LoRusso as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:30 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05053971 · Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsNational Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma · principal investigator
- Ph1NCT03925428 · Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasNational Cancer Institute (NCI) · withdrawn · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT03878095 · Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsNational Cancer Institute (NCI) · active not recruiting · Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm · principal investigator
- Ph2NCT03212274 · Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma · principal investigator
- Ph2NCT02849496 · Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerNational Cancer Institute (NCI) · active not recruiting · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma · principal investigator
- Ph1NCT01163071 · A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or LymphomasCelgene · terminated · Advanced Solid Tumors · principal investigator
- Ph1NCT00576654 · Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma · principal investigator
- N/ANCT00369109 · Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid TumorsBarbara Ann Karmanos Cancer Institute · completed · Breast Cancer, Colorectal Cancer, Pancreatic Cancer · study chair
- Ph1NCT00352443 · S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaSWOG Cancer Research Network · completed · Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00002585 · Pyrazoloacridine in Treating Women With Metastatic Breast CancerBarbara Ann Karmanos Cancer Institute · completed · Breast Cancer · study chair
- Ph1NCT00002923 · KRN5500 in Treating Patients With Metastatic Solid TumorsBarbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph1NCT00003250 · Fenretinide in Treating Patients With Solid TumorsBarbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph1NCT00028548 · XK469 in Treating Patients With Advanced Solid TumorsBarbara Ann Karmanos Cancer Institute · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.UH2CA271205 · NCI · YALE UNIVERSITY · fiscal years 2025 to 2026 · $210,089 awarded in 2026Same name and institution; not confirmed by an ID
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · fiscal years 2014 to 2026 · $2,075,171 awarded in 2026Grant number is on one of their registry trials
- Early Clinical Trials of New Anti-Cancer AgentsU01CA062487 · NCI · WAYNE STATE UNIVERSITY · fiscal years 1996 to 2013 · $620,359 awarded in 2013Grant number is on one of their registry trials
- Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus IrinotecanR21CA135572 · NCI · WAYNE STATE UNIVERSITY · fiscal years 2008 to 2009 · $338,176 awarded in 2009Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT02849496
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT02849496
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026Named on NCT02849496
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026Named on NCT02849496
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026Named on NCT02849496, NCT00576654
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 2008 to 2013Named on NCT00576654
- Cancer Research Training and Education CoordinationP30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Morhaf Al Achkar · fiscal years 2007 to 2026
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 2008 to 2013Named on NCT00352443
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:30 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.Clin Cancer Res · 201875 citationsRCR 2.5